Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)

Bringing migration research under one roof.

Funded by Led by

This project was made possible thanks to funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement Ares(2017) 5627812-77012.